Humatech Stock

Humatech EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Humatech (HUMT) as of Jul 16, 2026 is -1.14.

EV/EBIT

-1.14

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Humatech is 2026 -1.14 . EV/EBIT (Enterprise Value to EBIT) of Humatech was 2025 - . It decreases by % lower compared to the previous year.

The Humatech EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2001
-16.97 base
Jan 1, 2002
-4.30 base
Jan 1, 2003
-1.58 base
Jan 1, 2004
-1.97 base
Jan 1, 2005
-1.78 base
Jan 1, 2006
-3.18 base
YEARPRICE-TO-EBIT
2006 -3.18
2005 -1.78
2004 -1.97
2003 -1.58
2002 -4.30
2001 -16.97
Access this data via the Eulerpool API

Humatech Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Humatech's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Humatech's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Humatech's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Humatech grows earnings faster than its peers.

Humatech Stock analysis

What does Humatech do? Humatech Inc is an international company that specializes in the development, production, and marketing of products for the healthcare industry. The company was founded in 1983 and has since adapted its business models and strategies to meet the changing demands of the market. It is now headquartered in Virginia, USA and operates on multiple continents. The business model of Humatech Inc focuses on the manufacturing of diagnostic and testing products for laboratory and clinical facilities. These products are designed for the diagnosis of diseases such as cancer, diabetes, pregnancy, thyroid problems, and many others. The company also offers HIV, hepatitis, and troponin tests. The high quality of these products has helped the company establish strong brand recognition and customer loyalty. In addition to its products, Humatech Inc also provides services in various areas to offer comprehensive solutions tailored to individual needs. These services include consulting, software solutions, and training, contributing to optimized and efficient operations in medical facilities and laboratories. The different divisions of Humatech Inc encompass a wide range of products and services. The category of diagnostic and testing products forms the core of the company, including tests for diabetes, pregnancy, thyroid problems, cancer, HIV, and hepatitis. The range also includes specialized tests for kidney problems and heart diseases. The company is constantly striving to expand its range of tests for new health issues. Under the category of consulting services, Humatech Inc offers in-depth knowledge of current medical developments, diagnostic procedures, and testing methods. Customers can choose from a wide range of services, including the development of specific test procedures, marketing support, and workflow optimization. The "software solutions" business field includes a variety of online tools to support diagnostic procedures and tests. The software allows medical facilities and laboratories to automate their workflow, manage and analyze data, and quickly retrieve test results. To provide customers with added value, Humatech Inc also offers a range of training programs. These not only cover the operation and application of the products, but also teach optimal work and result processes. Overall, Humatech Inc is an important player in the healthcare industry. By focusing on the development and marketing of diagnostic and testing products, the company is able to sustainably convince its customers through high product quality and services. The wide product range, services, and extensive network of employees, consultants, and customers make the company a forward-thinking service provider. Humatech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humatech stock

EV/EBIT (Enterprise Value to EBIT) of Humatech is -1.14 in 2026.

Access this data via the Eulerpool API

Valuation — Humatech

All Key Metrics — Humatech